Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ERAB contains a putative noncleavable signal peptide

K Sambamurti1, D K Lahiri

  • 1Department of Pharmacology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, Florida, 32224, USA.

Biochemical and Biophysical Research Communications
|August 26, 1998
PubMed
Summary

Amyloid beta (Abeta42) protein is toxic in Alzheimer's disease (AD). We identified endoplasmic-reticulum associated Abeta binding protein (ERAB) as a type II integral membrane protein, explaining Abeta binding and AD pathogenesis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blood biomarkers for memory: toward early detection of risk for Alzheimer disease, pharmacogenomics, and repurposed drugs.

Molecular psychiatry·2019
Same author

Melatonin Treatment Enhances Aβ Lymphatic Clearance in a Transgenic Mouse Model of Amyloidosis.

Current Alzheimer research·2018
Same author

Novel roles of amyloid-beta precursor protein metabolites in fragile X syndrome and autism.

Molecular psychiatry·2016
Same author

Abnormal cerebrospinal fluid (CSF) dynamics in Alzheimer's disease and normal pressure hydrocephalus: CSF-amyloid β precursor protein metabolites as possible biomarkers.

European journal of neurology·2012
Same author

Epigenetics: a paradigm shift in understanding Alzheimer's disease.

Current Alzheimer research·2012
Same author

Current drug targets for modulating Alzheimer's amyloid precursor protein: role of specific micro-RNA species.

Current medicinal chemistry·2011

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Biochemistry

Background:

  • Amyloid beta (Abeta42) is a key neurotoxic protein implicated in Alzheimer's disease (AD).
  • Endoplasmic-reticulum associated Abeta binding protein (ERAB) was previously identified as an Abeta-binding protein involved in Abeta-induced apoptosis.
  • Initial studies suggested ERAB lacked a signal sequence, implying cytoplasmic membrane localization, which conflicted with Abeta's secretory pathway generation.

Purpose of the Study:

  • To investigate the subcellular localization and Abeta-binding mechanism of ERAB.
  • To re-evaluate the topology of ERAB in light of Abeta's cellular processing.
  • To elucidate the role of ERAB's membrane association in Alzheimer's disease pathogenesis.

Main Methods:

  • Bioinformatic analysis of the ERAB protein sequence to identify potential signal peptides.

Related Experiment Videos

  • Comparative analysis of ERAB sequences across species (human, rodent, bovine).
  • In silico prediction of ERAB's membrane topology as a type II integral membrane protein.

    • Main Results:

    • A putative signal peptide was detected in the ERAB sequence via computer analysis.
    • This signal sequence was conserved across human, rodent, and bovine ERAB orthologs.
    • The presence of a signal peptide suggests ERAB is a type II integral membrane protein, allowing Abeta binding within secretory organelles.

    Conclusions:

    • The findings indicate ERAB is a type II integral membrane protein, not solely cytoplasmic.
    • This revised topology explains how ERAB can bind Abeta within the lumen of transport vesicles.
    • This provides a molecular basis for understanding ERAB's critical role in Abeta-mediated neurotoxicity and Alzheimer's disease progression.